Genetically engineered anti-CD20-IFN-α fusion proteins exert direct cytotoxicity and overcome CD20 mAb resistance in mice bearing B-cell lymphoma xenografts [58]. This evidence concerns the gene IFNA17 and B-cell non-Hodgkin lymphoma.